Objective: Therefore, we tested whether IKK2 is an MLCK in living cells and the role of IKK2 in mediating vasoconstriction and blood pressure regulation. 
I
nitiation of vascular smooth muscle contraction is primarily regulated at the level of myosin light chain (MLC) Ser19 phosphorylation, which is essential for interaction of actin and myosin and activation of actin-activated myosin ATPase. 1 The relative activity of MLC kinases (MLCKs) versus MLC phosphatase (MLCP) ultimately determines the phosphorylation level of MLC Ser19 and, thus, vascular contractile responses.
Previous studies have demonstrated that, in addition to the classic Ca 2+ -dependent MLCK, 2 another unidentified kinase(s) also contributes to MLC phosphorylation in living cells. For example, basal MLC phosphorylation in vascular smooth muscle cells (VSMCs) is resistant to MLCK inhibitors ML-7 3, 4 and ML-9. 5 MLCP inhibition with calyculin A or microcystin-LR induces potent vasoconstriction; these contractile responses are also resistant to MLCK inhibitors, [6] [7] [8] indicating that a kinase(s) other than the classic MLCK is primarily responsible for MLC phosphorylation. The most direct evidence comes from studies in MLCK-deficient mice, showing that blood vessels from these mice remain responsive to elevated [Ca 2+ ] i , strongly suggesting that a kinase(s) other than MLCK phosphorylate MLC in VSMCs. 9 
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Thus far, several kinases other than MLCK have been shown to phosphorylate MLC Ser19 in vitro, including Rhoassociated protein kinase, 10 integrin-linked kinase (ILK), 11 p21-activated kinase (PAK), 12 and zipper-interacting protein kinase (ZIPK). 13 However, it remains controversial whether these kinases phosphorylate MLC in living cells. The Rho-Kinase inhibitor Y-27632 has no effect on calyculin A-induced vasoconstriction and MLC phosphorylation, 14 suggesting that Rho-Kinase may not be an important MLCK in VSMCs. Two potent ZIPK inhibitors, AV25 and SM1, do not relax MLCP inhibition-induced vasoconstriction, 15 ruling out the possibility that ZIPK phosphorylates MLC in this context. PAK1, one of the most intensively studied PAKs, contributes to MLC phosphorylation in neurons, 17 breast carcinoma cells, 18 Hela cells, 19 and pulmonary endothelial cells. 20 However, dominant-negative PAK or shRNA induces myoepithelial cell contraction, in contrast to the expected relaxation. 21 In guinea pig VSMCs, PAK1 also induces relaxation through phosphorylation and subsequent inhibition of MLCK, 22 raising doubt on the role of PAKs' MLCK activity in VSMCs. ILK activity in permeable esophagus smooth muscle cells is increased in response to MLCP inhibition by okadaic acid, and ILK antibody inhibits okadaic acid-induced cell shorting, indicating that ILK may be an important intracellular MLCK. However, except for results that ILK phosphorylates MLC in cell-free phosphorylation reaction, evidence that ILK is an MLCK in VSMCs primarily comes from studies that AV25 and SM1 do not inhibit ILK. 15 Therefore, the nature of unidentified MLCK(s) in VSMCs remains to be determined.
Inhibitor κB (IκB) kinase 2 (IKK2) was initially identified as a kinase subunit of the IKK complex. 23, 24 Its essential role in IκB protein phosphorylation and subsequent nuclear factor κB (NF-κB) activation has been well established. 25, 26 In addition to IκB proteins, IKK2 phosphorylates other substrates, such as insulin substrate 1, 27 14-3-3β, 28 B-cell lymphoma/leukemia 10, 29 forkhead box O3, 30 and synaptosomal-associated protein 23, 31 demonstrating its extensive role in cellular responses. The importance of IKK2 in cell function is further illustrated by the fact that IKK2-deficient mice are embryonically lethal because of liver degeneration. 26 Notably, IKK2 −/− mouse embryonic fibroblasts are abnormal in migration and morphology, 32 2 MLC phosphorylation-dependent cellular responses. Therefore, we tested the hypothesis that IKK2 regulates MLC phosphorylation in VSMCs, and that IKK2 is important in mediating vascular contractile responses to several agonists as well as in blood pressure regulation.
Methods
An expanded Methods section can be found in the Online Data Supplement.
Generation of Smooth Muscle-Specific IKK2-Deficient Mice

IKK2
flox/flox mice were generated as previously described. 33 
Blood Pressure Measurements
The 20-week-old IKK2 smKo mice (n=7) and littermate control mice (n=5) were implanted with radiotelemeter probes as previously described 34 (model TA11PA-C10; Data Sciences International). Ten days after surgery, we began monitoring 24-hour mean arterial pressure and heart rate for 5 consecutive days.
We also measured blood pressure in younger mice by the tail cuff method. IKK2 smKo mice (n=16), and littermate WT control mice (n=16) were trained beginning at the age of 6 weeks for 2 weeks (daily, 5 d/wk), and then systolic blood pressure was recorded beginning at the age of 8 weeks for 2 weeks (daily, 5 d/wk). The average systolic blood pressure during this period was recorded.
To measure 24-hour mean arterial blood pressure in TNFR1
smKo, and control littermate mice (n=6/group) were implanted with radiotelemeter probes as previously described. 34 After 8 days of recovery, mean arterial pressure and heart rate were recorded for 4 consecutive days. For analyzing the acute effects of angiotensin II (0.3 µg/kg), phenylephrine (PE; 10 µg/kg), thromboxane (30 µg/kg), and sodium nitroprusside (32 µg/kg), those mice were also implanted with catheter inserted into the jugular vein for drug infusion. After a 30-minute stabilizing period, bolus injections of vasoactive drugs were administered at 30-minute intervals.
Cell Culture
A human aortic VSMC line (HVSMCs, ATCC#: CRL-1999) was purchased from ATCC. The cells were maintained in DMEM supplemented with 10% fetal bovine serum. Treatments were applied to cells ≈90% confluent in 60 mm dishes.
To measure MLC phosphorylation, cells were serum-starved for 2 hours and then treated with the indicated compounds followed by washing with ice-cold PBS once. The cell lysates were then prepared with radioimmunoprecipitation assay buffer supplemented with Halt Protease and Phosphatase Inhibitor Cocktail (Pierce) on ice. The MLC phosphorylation levels were determined by Western blot analysis with mouse antiphospho-MLC 2 (Ser19, Cell Signaling Technology) and mouse anti-MLC (Sigma).
Transfection
Lipofectoamine 2000 transfection reagent was used to perform transfection with plasmids, according to manufacturer instruction. Briefly, HVSMCs (10 6 cells per 60 mm dish) were seeded 1 day before transfection. Transfection complex was prepared at DNA (μg): Lipofectamine 2000 (μL) ratio of 1:1.
Western Blotting
Western blotting was performed using standard techniques as previously reported 35 with primary antibodies as follows: mouse antiphospho-MLC 2 (Ser19, Cell Signaling Technology), mouse anti-MLC (Sigma), rabbit anti-IκBα (Cell Signaling Technology), monoclonal antiβ-actin (Sigma), rabbit anti-IKK2 (Sigma), rabbit anti-IKK1 (Sigma), mouse antiphospho-IκBα (Ser32/36, Cell Signaling Technology), mouse anti-myosin phosphatase target subunit 1 (BD Transduction Laboratories), and rabbit antiphospho-myosin phosphatase target subunit 1 (Thr696, Upstate). Signals were detected by chemiluminescence and analyzed by densitometry.
Vascular Reactivity
Reactivity of rat and mouse aortic rings to several vasoactive agonists was assessed as previously described. 35 IκB Kinase Peptide Inhibitor, NF-kB Activation Inhibitor II (JSH-23), and SC-514 were purchased from EMD Chemicals. All other materials were purchased from Sigma. The experimental protocols for this study were approved by 36 A resting tension of 30 mN (rats) or 4 mN (mice) was imposed on each ring, and the rings were allowed to equilibrate for 1 hour. Arterial integrity was assessed first by stimulation of vessels with 80 mmol/L KCl. Endothelium-integrity was assessed by measuring the dilatory response to acetylcholine (10 µmol/L) in PEcontracted vessels (3 µmol/L). The failure of acetylcholine to relax denuded aortic rings was considered proof of endothelium disruption.
To analyze the responses of mesenteric arteries, male WT and IKK2 smKo mice (8-10 weeks old) were killed with an overdose of sodium pentobarbital (120 mg/kg IP). The mesentery was rapidly removed and placed in ice-cold gassed (95% O 2 and 5% C O2 ) physiological salt solution. The second-order mesenteric arteries were dissected free of adipose and connective tissue and immediately were mounted in a wire myograph (Danish MyoTechnology, Aarhus, Denmark). After an initial 30-minute equilibration, vessel wall tension and diameter were normalized in a standardized procedure and stabilized for 1 hour. Wire myography was used to assess the KCl-, PE-or U-46619-induced contractile responses of arteries.
In Vitro Phosphorylation
The assays were established based on HTScan kinase assay kit (Cell signaling technology); 100 ng IKK2 in the kit or other kinases (MLCK and Zip-kinase from Upstate and Rho-associated protein kinase 1 from Abcam) were incubated with 0.75 µmol/L MLC (Calbiochem) or 0.75 µmol/L IκBα (Biomol) at 37°C in a total of 50 µL buffer containing 60 mmol/L HEPES-NaOH (pH 7. 2 , and 1 μmol/L calmodulin. Reaction was stopped by adding 50 µL SDS-PAGE sample buffer and boiling for 5 minutes.
Kinetic Analyses
Assays were performed by ProQinase. Recombinant, insect cellexpressed IKK2 protein was used as full-length, GST-tagged fusion protein (ProQinase #0258-00001 LOT008). Substrate peptide MLC-tide (KKRPQRATSNVFS-amide) was supplied by Penninsula Laboratories. Radiometric Filter Binding Assay was used to determine kinetics. Recombinant IKK2 (50 ng/well) was incubated with its substrate MLC-tide (various amounts) and cosubstrate ATP (various amounts) containing radioactive 33Pγ-ATP as a tracer in a constant ratio. Phosphorylated peptide was bound to MSPH-Filter plates (Millipore #MSPHN0B10), washed, and bound radioactivity was detected by liquid scintillation counting. In detail, assay components were added to a final volume of 50 μL in a 96-well PP V-bottom plate in assay mix (70 mmol/L HEPES pH7.5; 3 mmol/L MgCl 2 ; 3 mmol/L MnCl 2 ; 3 μmol/L Na-orthovanadate; 1,2 mmol/L DTT; 50 μg/mL PEG20,000; ATP and MLC-tide in various amounts; IKK-β 50 ng/well) in the following order: Assay buffer, MLC-tide, IKK2, and ATP. The assay was mixed and incubated for 20 minutes at 30°C. The reaction was stopped by addition of 20 μL 10% H 3 PO 4 . The MSPH-filter plate was washed with 20 μL 100% ethanol followed by 200 μL 150 mmol/L H 3 PO 4 , the reaction mixture was transferred to the filter plate and incubated for 30 minutes at room temperature. The mixture was passed through the filter by application of vacuum, washed 3× with 200 μL 150 mmol/L H 3 PO 4 and once with 20 μL 100% ethanol. After drying the plate, 50 μL/well of liquid scintillator was added, and bound radioactivity was determined by measurement in a liquid scintillation counter.
Statistical Analysis
P values for a type 1 error (α error) of <0.05 were considered significant. Student t test or ANOVA was used, as appropriate, for statistical analyses with GraphPad Instat 5 software (GraphPad Instat Software, San Diego, CA).
Results
IKK2 Phosphorylates MLC In Vitro
To investigate whether IKK2 phosphorylates MLC in vitro, we performed in vitro phosphorylation reactions with recombinant IKK2 and MLC and analyzed MLC Ser19 phosphorylation by Western blotting. Consistent with our hypothesis, IKK2 time-and dose-dependently increased MLC phosphorylation at a rate comparable with IκBα phosphorylation ( Figure 1A-1D ). The velocity of MLC phosphorylation by IKK2 was ≈36% of that by the classic MLCK ( Figure 1E and 1F), the best established MLCK in vivo. The maximal MLC phosphorylation by IKK2 was similar to that by the classic MLCK (Online Figure I) . To rule out the possibility that recombinant IKK2 was contaminated by the classic MLCK, we assessed the effect of ML-9, an MLCK inhibitor, and ethylene glycol tetraacetic acid, a Ca 2+ chelator that inhibits the classic MLCK activity, on the in vitro phosphorylation reaction. Online Figure II demonstrates that neither ML-9 nor ethylene glycol tetraacetic acid inhibited IKK2-induced MLC phosphorylation. Online Figure III reveals that IKK2 also phosphorylated intact myosin, further supporting that the MLCK activity of IKK2 may be physiologically significant.
Further supporting the in vitro MLCK activity of IKK2, Online Figures IV and V show that SC-514, an IKK2 inhibitor, 37 decreased MLC phosphorylation by IKK2 but not other MLCKs, including classic MLCK, Zip-kinase, and Rhoassociated protein kinase 1. More importantly, the reaction was also inhibited by IκBα-tide, an IKK2 substrate peptide derived from IκBα ( Figure 1G and 1H) , and the calculated K MLC was comparable with K IκBα (Online Table I ). Notably, although IKK1 and IKK2 share the IKK activity, IKK1 did not phosphorylate MLC in vitro (Online Figure VII) .
To determine whether the MLCK activity of IKK2 is biologically relevant, we performed kinetic analyses. Figure 1I and 1J reveal that the kinetics of MLC phosphorylation by IKK2 were similar to those of IκBα phosphorylation (Vmax: 3.7 and 2 μmol/mg per minute; K ATP : 2.7 and 0.5 μmol/L; Kpeptide: 1.7 and 1.4 μmol/L; MLC and IκBα, respectively), indicating that the MLCK activity of IKK2 may be biologically important.
IKK2 Phosphorylates MLC in Living Cells
To examine whether IKK2 is an MLCK in living VSMCs, we overexpressed IKK2 in human VSMCs (HVSMCs). Consistent with our in vitro results, IKK2 overexpression significantly increased the phosphorylation level of MLC Ser19 but not the regulatory subunit of MLCP myosin phosphatase target subunit 1 Thr696 (Figure 2A and 2B ).
We next analyzed whether endogenous IKK2 is an MLCK in living cells. Figure 2C and 2D and Online Figure VIII show that SC-514 treatment markedly attenuated the basal MLC phosphorylation and MLC phosphorylation in response to angiotensin II, U-46619 (a thromboxane mimetic), or ionomycin in HVSMCs. Notably, if compared with the basal level, those agonists markedly increased MLC phosphorylation even in the presence of SC-514 ( Figure 2C and 2D) , suggesting that IKK2 mainly contributes to the basal but not agonist-induced MLC phosphorylation. We also tested the MLC phosphorylation effect of a cell-permeant IKK2 inhibitory peptide. 38, 39 Consistent with the SC-514 results, the IKK2 peptide inhibitor markedly decreased the basal MLC phosphorylation in HVSMCs ( Figure 2E and 2F) . To exclude the possibility that IKK2 inhibitors decrease MLC phosphorylation through nonspecificactions, we analyzed the MLC phosphorylation effect of SC-514 in IKK2-deficient mouse embryonic fibroblasts. 32 Figure 2G and 2H show that SC-514 markedly decreased MLC phosphorylation levels in WT but not in IKK2 −/− mouse embryonic fibroblasts, strongly supporting that SC-514 decreases MLC phosphorylation via targeting IKK2. Notably, consistent with its proposed role in MLC phosphorylation, IKK2 −/− mouse embryonic fibroblasts had lower basal MLC phosphorylation level ( Figure 2G and 2H ).
IKK2 Is Implicated in Vasoconstriction
To assess the physiological importance of the MLCK activity of IKK2, we analyzed the role of IKK2 in vasoconstriction, an MLC phosphorylation-dependent physiological process. Figure 3A shows that SC-514 caused relaxation in endothelium-denuded rat aortic rings precontracted with PE, KCl, U-46619 (a thromboxane mimetic), or calyculin A (MLCP inhibitor). To establish a high level of intracellular Ca
2+
, we treated endothelium-denuded aortic rings with the Ca 2+ ionophore, ionomycin. This contraction was markedly relaxed by SC-514 ( Figure 3B ), suggesting that SC-514 does not cause relaxation by lowering intracellular Ca
. Next, we used SC-514 to further document the role of IKK2 in vasoconstriction. Figure 3C reveals that SC-514 relaxed PE-induced contraction with a half maximal inhibitory concentration (IC 50 ) comparable with that of inhibiting IKK2 in vitro. 37, 40 Consistent with the effect of SC-514, IKK2 inhibitory peptide, but not control peptide, significantly relaxed PE-induced contraction ( Figure 3D and 3E) , confirming the involvement of IKK2 in vasoconstriction. In contrast, a classic MLCK inhibitor ML-9 potently relaxed PEinduced endothelium-denuded rat aortic ring contraction, but had little effect on calyculin A-induced contraction (11±7% of precontraction; n=4; Figure 3F ), suggesting that SC-514 did not primarily target the classic MLCK for its vasodilator actions at least in calyculin A-induced contraction. However, we cannot completely exclude the possibility that SC-514 relaxed PE-induced contraction through inhibition of MLCK.
IKK2 inhibition induces apoptosis in diverse cell types. 41 However, the vasodilator action of IKK2 inhibitors is unlikely because of decreased viability of smooth muscle cells because the IKK2 inhibitory peptide-induced decrease in vasoconstriction recovered in hours ( Figure 3D ), and the vascular effect of 30 µmol/L SC-514 was completely reversible by washing (Online Figure IX) . In addition, although NF-κB is the best known downstream molecule from IKK2, it is not involved in the vasodilator action of IKK2 inhibitors because the action was observed within seconds, and JSH-23, an NF-κB antagonist A representative result from 4 independent experiments is presented. C, Endothelium-denuded rat aortic rings were contracted by PE (1 µmol/L), and the IKK2 inhibitor SC-514 was added in an accumulative manner. Results were expressed as percentage of precontraction. D and E, Phenylephrine (PE; 1 μmol/L) precontracted endothelium-denuded rat aortic rings were treated with IKK2 inhibitory or control peptide (the same peptides as in Figure 2E and 2F; 50 µg/mL). The representative recordings (C) and the quantification data (D) are presented. n=3. *P<0.05 vs control; Student t test. F, Endothelium-denuded rat aortic rings were contracted with calyculin A, followed by adding ML-9 (100 µmol/L). After washing, the rings were contracted with PE again and followed by ML-9 (100 µmol/L). A representative result from 3 independent experiments is presented.
that inhibits NF-κB binding to DNA, but not IKK2 activation, 42 did not have a similar vasodilator action (Online Figure X) .
To confirm the role of IKK2 in vasoconstriction, we generated smooth muscle-specific IKK2-deficient mice (IKK2   smKo   ) . Western blot analysis demonstrated that IKK2 smKo mice had a 58% decrease in aortic IKK2 protein expression ( Figure 4A and 4B). In agreement with the proposed role of IKK2 in vasoconstriction, aortic MLC phosphorylation in IKK2 smKo mice was decreased by 41% ( Figure 4A and 4B) . In contrast, IKK2 smKo mice had comparable IKK2 expression and MLC phosphorylation in the kidney (Figure 4A and 4B) . Further supporting the importance of IKK2 in vasoconstriction, IKK2 deficiency significantly reduced aortic vasoconstrictor responses to KCl or PE (Online Figure XIA and XIB) , and SC-514 had markedly decreased vasodilator action in IKK2-deficient mouse aortic rings (Online Figure XIC) . Given the important role of resistant arteries in blood pressure regulation, we further documented the vascular contractile responses in mesenteric arteries. Figure 4C -4E revealed that IKK2 deficiency in VSMCs markedly reduced contraction of mesenteric arteries induced by KCl, PE, or U-46619. Notably, mesenteric arteries from IKK2 smKo mice had significantly decreased relaxation responses to acetylcholine and SC-514 ( Figure 4F and 4G ).
IKK2 Deficiency Decreases Vascular Contractile Response and Basal Blood Pressure
To investigate the physiological role of IKK2, we measured 24-hour mean arterial blood pressure of IKK2 smKo mice using telemetry as previously described. 34 Unexpectedly, no significant change in mean arterial blood pressure was observed (WT versus IKK2 smKo : 99±1 versus 102±6 mm Hg; n=5 or 7/group; P=24.6%, Student t test). However, 20-week-old IKK2 smKo mice developed severe dermatitis (data not shown), which may have tended to increase blood pressure as a consequence of inflammation 43, 44 and, thus, oppose the blood pressure lowering effect of smooth muscle-specific IKK2 deficiency. Supporting this concept, we observed lower systolic blood pressure in 8-to 10-weekold IKK2 smKo mice (WT versus IKK2 smKo : 105±9 versus 98±10 mm Hg by the tail cuff method; n=16/group; P<0.05, Student t test).
IKK2 deficiency-induced dermatitis is TNFR1 dependent. 45 To further test the role of IKK2 in blood pressure regulation, we generated a mouse model with whole body TNFR1 deficiency and smooth muscle-specific IKK2 deficiency (TNFR1 −/− IKK2 smKo ). As expected, these mice did not develop dermatitis. Supporting the important role of IKK2 in blood pressure regulation, TNFR1
−/− IKK2 smKo mice had lower 24-hour mean blood pressure as measured by telemetry ( Figure 5A ). To verify that IKK2 regulates blood pressure through regulating MLC phosphorylation, we assessed the acute blood pressure responses to 3 vasoconstrictors (thromboxane, PE, and angiotensin II) each with a different mechanism of action. Figure 5B -5D demonstrates that TNFR1 −/− IKK2 smKo mice had markedly reduced hypertensive responses to those vasoconstrictors. In contrast, the vasodilator sodium nitroprusside, a nitric oxide donor, produced similar decreases in blood pressure in TNFR1 −/− and TNFR1 −/− IKK2 smKo mice ( Figure 5E ).
Discussion
In [3] [4] [5] In addition to the classic MLCK, several kinases, including Rho-Kinase, 10 ILK, 11 PAK, 12 and ZIPK, 13 can phosphorylate MLC in vitro. However, except for ILK, the MLCK activity of those kinases has been shown not to be of physiological significance. 14, 15, 21 To our knowledge, this is the first study demonstrating that a kinase other than the classic MLCK regulates VSMC MLC phosphorylation as an MLCK, contributes to vascular contractile responses, and, is important in blood pressure regulation.
Previous studies have shown that the basal MLC phosphorylation is independent of the classic MLCK because its inhibitors have no effect on the basal MLC phosphorylation. [3] [4] [5] However, the factors that contribute to basal MLC phosphorylation in VSMCs have not been previously elucidated. Our data demonstrate that IKK2 contributes importantly to basal MLC phosphorylation in VSMCs. Given that various vasoconstrictor agonists induce further MLC phosphorylation, in excess of basal MLC phosphorylation, IKK2 may be implicated in diverse vascular contractile responses. This conclusion is consistent with our results demonstrating that IKK2 inhibition markedly reduced basal MLC phosphorylation and vasoconstrictor responses to all tested agonists. However, the mechanisms whereby IKK2 regulates cellular MLC phosphorylation in different physiological and pathophysiological conditions remain to be determined.
Although our results indicate that IKK2 plays a key role in basal MLC phosphorylation, its role in stimulating further MLC phosphorylation in response to vasoconstrictors is less clear. We found that vasoconstrictors increased MLC phosphorylation even in the presence of an IKK2 inhibitor, suggesting that IKK2 may not be essential for agonist-induced MLC phosphorylation. In addition, because IKK2 inhibition relaxed all tested contractions (agonist-induced MLC phosphorylation can be through diverse pathways and thus less likely to be inhibited by a single inhibitor, whereas basal MLC phosphorylation definitely contributes to all contractions), it is more likely that the contribution of IKK2 to agonist-induced MLC phosphorylation may be trivial. However, this remains to be determined. Unfortunately, the methods commonly used to determine the phosphorylation level of cellular MLC, such as the one used in the present study and urea-glycerol gel, are only semiquantitative. It may be necessary to assess the contribution of IKK2 to agonist-induced MLC phosphorylation with more quantitative methods, such as isotope tracers, in the future. Our finding that pharmacological blockade of IKK2 or VSMC-specific genetic deficiency of IKK2 markedly attenuates vasoconstrictor responses to several agonists with different modes of action and reduces blood pressure suggests that IKK2 may be important in agonist-induced as well as basal MLC phosphorylation in VSMCs.
Another interesting aspect of IKK2 as an MLCK is that in contrast to the Ca 2+ -dependent activation of the classic MLCK, the MLCK activity of IKK2 seems to be Ca 2+ independent because the Ca 2+ chelator ethylene glycol tetraacetic acid does not have an inhibitory effect on the IKK2-induced MLC phosphorylation in vitro. This is consistent with our results, demonstrating that IKK2 plays an important role in cellular basal MLC phosphorylation. Notably, although the MLCK activity of IKK2 is Ca 2+ independent, it could theoretically enable Ca 2+ -dependent MLC phosphorylation and contraction in the absence of classic MLCK. The MLCK activity of IKK2 is antagonized by the active MLCP in the absence of agonists, which maintains MLC phosphorylation at a low level. As agonists increase [Ca 2+ ] i and subsequently inhibit the antagonizing MLCP through recently identified Ca 2+ -dependent signaling pathways, 46 IKK2 then can increase MLC phosphorylation through its MLCK activity and consequently induce contraction. Therefore, it will be particularly interesting to determine whether the vasoconstriction of MLCK-deficient mice is dependent on the MLCK activity of IKK2 in future studies.
Consistent with the proposed role of IKK2 in the regulation of MLC phosphorylation, our data also show that VSMCspecific IKK2 deficiency on the genetic background of TNFR1 deficiency results in a significant reduction in blood pressure. Furthermore, mice with VSMC-specific IKK2 deficiency had reduced hypertensive responses to all vasoconstrictor agonists tested. These observations suggest that IKK2 may be a potential target for antihypertensive treatment. However, further studies are needed to assess the blood pressure lowering effect of IKK2 inhibitors in diverse hypertensive animal models.
In conclusion, our study reveals that IKK2 is an important MLCK in living cells and is critical in vascular smooth muscle contractile regulation both in vitro and in vivo. Therefore, our observations provide a novel pathway for physiological regulation of vascular smooth muscle contraction that may be an important target for antihypertensive therapy.
